

Contents

1	Allocating Cancer-Directed Expenditures: Tensions Between Prevention, Early Detection and Treatment is Unnecessary	1
	Bruce E. Hillner and Thomas J. Smith	
1.1	Introduction	1
1.2	Our Life Expectancy and Cancer Success Stories	2
1.3	No Cure in Sight: Costs of Drugs, Gadgets, Genomics and Technology	2
1.4	Bending the Cancer Cost Curve	5
1.5	Conclusion	8
	References	8
2	Lessons Learned from Prevention Programs: Different Endpoints Should Be Used in Secondary and Tertiary Prevention	11
	Franz Porzsolt	
2.1	Introduction	11
2.2	Methods	12
2.3	Results	13
2.3.1	Traditional Outcomes of Treatment and of Prevention Programs	13
2.3.2	Proposal for the Evaluation of Prevention Programs	15
2.4	Discussion	16
2.4.1	The Risk of Interpretation in Prevention Programs	16
2.4.2	The Resulting Need for Evaluation of Preventive Medicine	17
2.4.3	Recommendations for Future Preventive Research	18
	References	18

3	Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities	21
	Barbara K. Dunn, Karin Jegalian, and Peter Greenwald	
	Abbreviations	21
3.1	Biomarkers: What They Are and How They Are Applied	23
3.1.1	Screening Biomarkers for Early Detection	23
3.1.2	Biomarkers as Surrogate Endpoints in Cancer Prevention Trials.	26
3.2	Breast Precancer and Cancer Prevention	28
3.2.1	Ductal Carcinoma In situ	30
3.2.2	Tissue Stroma and Mammographic Density	31
3.2.3	Biomarkers, ER-Positive Breast Cancer, and Breast Cancer Prevention Trials.	31
3.2.4	Biomarkers and Estrogen Receptor-Negative Breast Cancers	33
3.2.5	Access to Breast Tissue for Biomarker Evaluation.	33
3.2.6	Biomarkers in Phase 2 Chemoprevention Trials.	34
3.3	Prostate Cancer Prevention	35
3.3.1	PSA Screening and Early Detection of Prostate Cancer.	35
3.3.2	Phase 3 Prostate Cancer Prevention Trials	35
3.3.3	Discovery of New Biomarkers for Early Detection of Prostate Cancer.	36
3.4	Colorectal Cancer Prevention	37
3.5	Lung Cancer Prevention	38
3.5.1	Molecular Markers for Early Detection and Prognosis	39
3.5.2	Treating Nicotine Addiction	40
3.5.3	Fluorescence Bronchoscopy	40
3.6	Conclusions.	40
	References.	40
4	Targeting Polyamines and Inflammation for Cancer Prevention	49
	Naveen Babbar and Eugene W. Gerner	
4.1	Introduction.	50
4.2	Polyamines, Inflammation, and Cancer	50
4.2.1	Polyamine Metabolism	50
4.2.2	Polyamines and Cancer.	52
4.3	Roles of Inflammation and Polyamines in Prostate Cancer	53
4.3.1	Polyamines and Prostate Cancer.	53
4.3.2	Polyamines, Inflammation, and Prostate Cancer	53
4.3.3	Targeting Polyamines and Inflammation in Prostate Cancer	54
4.4	Roles of Inflammation and Polyamines in Colon Cancer.	55
4.4.1	Polyamines and Colon Cancer	55
4.4.2	Polyamines, Inflammation, and Colon Cancer	56
4.4.3	Targeting Polyamines and Inflammation in Colon Cancer	56

4.5	Roles of Inflammation and Polyamines in Other Cancers	59
4.6	Conclusions	60
	References	60
5	Thinking About the Role (Largely Ignored) of Heavy Metals in Cancer Prevention: Hexavalent Chromium and Melanoma as a Case in Point	65
	Frank L. Meyskens and Sun Yang	
5.1	Background	65
5.1.1	The Evolution of the Idea	65
5.1.2	Substances That Bind Melanin	66
5.2	Major Risk Factors for Cutaneous Melanoma	67
5.2.1	Epidemiology	67
5.3	Metals	69
5.3.1	Chemistry and Genetic Damage	69
5.3.2	Chromium Chemistry	69
5.3.3	Upregulation of Metallothioneins (MTs)	70
5.3.4	Some Preliminary Experimental Data	70
5.4	Future Prospects	72
	References	72
6	Hepatitis B Virus and Cancer Prevention	75
	Mei-Hwei Chang	
6.1	Infection and Cancer	75
6.2	Disease Burden of Liver Cancer	77
6.3	Hepatitis B Virus Infection and Hepatocellular Carcinoma	77
6.4	Cancer Prevention Against Hepatocellular Carcinoma	78
6.5	Hepatitis B Vaccination Program	79
6.6	Effective Reduction of Chronic HBV Infection by Universal Hepatitis B Immunization	79
6.7	The Effect on Liver Cancer Prevention by Vaccination	80
6.8	Problems and Strategies of Successful HCC Prevention by Hepatitis B Vaccination	81
6.9	Implications and Future Prospects	81
	References	82
7	Chemoprevention of Hepatocellular Carcinoma in Chronic Hepatitis C	85
	Timothy R. Morgan	
7.1	Hepatitis C	85
7.2	Hepatocellular Carcinoma	86
7.3	Prevention of Hepatocellular Carcinoma	87
7.3.1	Curative Treatment	87

7.3.2	Treatments That Suppress Hepatitis C Virus	88
7.3.3	Noncurative Chemoprevention	88
7.3.4	Prospective Randomized Trials: Carotenoids and Phytochemicals	88
7.3.5	Secondary Chemoprevention of HCC	89
7.3.6	Nonrandomized, Uncontrolled and/or Retrospective Clinical Trials	90
7.3.7	Epidemiologic Studies	91
7.3.8	Drugs Used to Treat Hepatocellular Carcinoma	92
7.3.9	Prevention of Hepatocellular Carcinoma in Cell Lines and Animal Models	92
7.3.10	Phase II Trial of S-Adenosylmethionine in Hepatitis C Cirrhosis	94
7.4	Conclusions	97
	References	97
8	Nutritional Aspects of Primary Prostate Cancer Prevention	101
	Hans-Peter Schmid, Claus Fischer, Daniel S. Engeler, Marcelo L. Bendhack, and Bernd J. Schmitz-Dräger	
8.1	Introduction	101
8.2	Dietary/Nutritional Factors	102
8.2.1	Dietary Fat	102
8.2.2	Obesity	102
8.2.3	Micronutrients	102
8.2.4	Vitamins	103
8.2.5	Minerals	103
8.2.6	Phytoestrogens	104
8.2.7	Diabetes Mellitus	104
8.3	American Cancer Society (ACS) Guideline	105
8.3.1	A: Try to Maintain a Healthy Weight	105
8.3.2	B: Take Regular Physical Exercise	105
8.3.3	C: Maintain a Healthy Diet with a Focus on Fruit and Vegetables	105
8.3.4	D: Reduce Alcohol Intake	105
8.4	Conclusions	106
	References	106
9	Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors	109
	Dipen J. Parekh	
9.1	Rationale for the Chemoprevention of Prostate Cancer	109
9.2	The Prostate Cancer Prevention Trial	110
9.3	Pathologic Characteristics of the Cancers in the Prostate Cancer Prevention Trial	110

9.4	Finasteride Increases Sensitivity of Prostate-Specific Antigen, Digital Rectal Examination and Biopsy Detection for Prostate Cancer.	111
9.4.1	Decreased Prostate Volume with Finasteride Increases Cancer Detection.	112
9.5	Side Effects of Finasteride	113
9.6	Conclusion	113
	References.	113
10	Hormone Replacement Therapy and Breast Cancer.	115
	Anthony Howell and Gareth D. Evans	
10.1	Background.	115
10.2	HRT Use in Women Diagnosed with Breast Cancer	116
10.2.1	Observational Studies	116
10.2.2	Randomised Trials	117
10.2.3	Effects of Withdrawal of HRT in Women with Breast Cancer.	117
10.3	HRT and Risk of Breast Cancer	118
10.3.1	Observational Studies	118
10.3.2	Randomised Studies	118
10.3.3	Withdrawal of HRT in Women Without Breast Cancer	119
10.3.4	Summary.	119
10.4	HRT After Oophorectomy in Women Less Than 50 Years of Age	119
10.4.1	Observational Studies	120
10.5	Coronary Heart Disease	120
10.6	Potential Biological Explanations.	121
10.7	Conclusions.	122
	References.	122
11	Physical Activity and Breast Cancer: Review of the Epidemiologic Evidence and Biologic Mechanisms.	125
	Christine M. Friedenreich	
11.1	Epidemiologic Evidence.	126
11.1.1	Background.	126
11.1.2	Methodologic Issues in Studies of Physical Activity and Cancer	126
11.1.3	Overall Associations Between Physical Activity and Breast Cancer Risk.	126
11.1.4	Type, Dose, and Timing of Activity	126
11.1.5	Population Subgroups.	128
11.1.6	Summary of Epidemiologic Findings	131
11.2	Biologic Mechanisms	132
11.2.1	Adiposity.	132
11.2.2	Sex Hormones.	132

11.2.3	Insulin-Related Factors	134
11.2.4	Adipokines and Inflammation.	134
11.2.5	Other Mechanisms	135
11.3	Conclusion	135
	References.	136
12	Prevention of Breast Cancer by Newer SERMs in the Future	141
	Trevor Powles	
12.1	Introduction.	141
12.2	Arzoxifene.	142
12.3	Lasodoxifene	142
12.4	Discussion.	143
12.5	Conclusions.	144
	References.	144
13	Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Needed	147
	Iván P. Uray and Powel H. Brown	
13.1	Introduction.	148
13.2	Endocrine Preventive Agents	148
13.3	Selective Estrogen Receptor Modulators	148
13.4	Aromatase Inhibitors.	151
13.5	New Strategies to Prevent Hormone-Independent Breast Cancer	152
13.5.1	PARP Inhibitors	152
13.6	Cell Growth Inhibitors	153
13.6.1	Statins	153
13.6.2	Metformin	153
13.6.3	Retinoids	154
13.6.4	PPAR Agonists	156
13.6.5	COX-2 Inhibitors	156
13.6.6	Tyrosine Kinase Inhibitors	157
13.6.7	The IGF System	158
13.6.8	Conclusions and Future Directions.	158
	References.	159

Clinical Cancer Prevention

Senn, H.-J.; Otto, F. (Eds.)

2011, X, 162 p. 7 illus., 4 illus. in color., Hardcover

ISBN: 978-3-642-10856-3